These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30168181)

  • 1. Infant onset severe complement-mediated hemolytic uremic syndrome complicated by secondary sclerosing cholangitis.
    Yesilbas O; Sevketoglu E; Petmezci MT; Kihtir HS; Benzer M; Arikan C; Berdeli A; Baloglu H; Baskan O
    J Clin Apher; 2018 Oct; 33(5):619-623. PubMed ID: 30168181
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemolytic uremic syndrome with multiple organ involvement secondary to complement factor H p.Arg1215X mutation.
    Yeşilbaş O; Şevketoğlu E; Petmezci MT; Kıhtır HS; Benzer M; Berdeli A
    Turk J Pediatr; 2017; 59(5):576-580. PubMed ID: 29745120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
    Sengul Samanci N; Ayer M; Ergen A; Ozturk S
    Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
    Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A
    J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute
    Han H; Alagusundaramoorthy S; Swanson K; Gardezi AI; Chan MR
    Perit Dial Int; 2019; 39(6):575-576. PubMed ID: 31690705
    [No Abstract]   [Full Text] [Related]  

  • 6. Innovative therapeutic approach: sequential treatment with plasma exchange and eculizumab in a pregnant woman affected by atypical hemolytic-uremic syndrome.
    Mussoni MP; Veneziano FA; Boetti L; Tassi C; Calisesi C; Nucci S; Rigotti A; Panzini I; Ardissino G
    Transfus Apher Sci; 2014 Oct; 51(2):134-6. PubMed ID: 25294113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
    Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V
    Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An international consensus approach to the management of atypical hemolytic uremic syndrome in children.
    Loirat C; Fakhouri F; Ariceta G; Besbas N; Bitzan M; Bjerre A; Coppo R; Emma F; Johnson S; Karpman D; Landau D; Langman CB; Lapeyraque AL; Licht C; Nester C; Pecoraro C; Riedl M; van de Kar NC; Van de Walle J; Vivarelli M; Frémeaux-Bacchi V;
    Pediatr Nephrol; 2016 Jan; 31(1):15-39. PubMed ID: 25859752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
    Rigothier C; Delmas Y; Roumenina LT; Contin-Bordes C; Lepreux S; Bridoux F; Goujon JM; Bachelet T; Touchard G; Frémeaux-Bacchi V; Combe C
    Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An unusual case of haemolytic uraemic syndrome following endoscopic retrograde cholangiopancreatography rapidly improved with eculizumab.
    Taton O; Delhaye M; Stordeur P; Goodship T; Le Moine A; Massart A
    Acta Gastroenterol Belg; 2016; 79(2):257-61. PubMed ID: 27382949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.
    Ariceta G
    Pediatr Nephrol; 2019 May; 34(5):943-949. PubMed ID: 30693384
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H.
    Madden I; Roumenina LT; Langlois-Meurinne H; Guichoux J; Llanas B; Frémeaux-Bacchi V; Harambat J; Godron-Dubrasquet A
    Pediatr Nephrol; 2019 Mar; 34(3):533-537. PubMed ID: 30560448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical Hemolytic Uremic Syndrome.
    Dixon BP; Gruppo RA
    Pediatr Clin North Am; 2018 Jun; 65(3):509-525. PubMed ID: 29803280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
    Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W
    N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.